HomeLatest NewsFederal NewsFDA approves powerful new opioid amid controversy

FDA approves powerful new opioid amid controversy

The Food and Drug Administration on Nov. 2 approved a new form of an extremely potent opioid, Dsuvia, just weeks after the chairman of the advisory committee that reviewed it asked the FDA to reject it on grounds that it would likely be abused.

Dsuvia, which is a tablet form of sufentanil, is 10 times stronger than fentanyl. Sufentanil is a synthetic opioid that has been used intravenously and in epidurals for over 20 years.

FDA Commissioner Dr. Scott Gottlieb emphasized that Dsuvia is delivered through a “pre-filled, single-dose applicator” and will only be permitted in hospitals, surgical centers and other medically supervised settings. It is ideally suited for certain special circumstances, Gottlieb said, particularly for soldiers wounded on the battlefield.

Dr. Raeford Brown, chairman of the analgesics and anesthetic products advisory committee, wrote a letter to Commissioner Gottlieb and other top FDA officials expressing deep concern regarding Dsuvia. Dr. Brown described Dsuvia as “an extremely divertible drug” and predicted diversion, abuse and death if the drug is made available.

Stay Connected

Unified Voice Newsletter

Events This Month

June

25junAll Day262024 Rural Health Leaders ConferenceSDAHO Event

25jun12:00 pm1:00 pmData Protection and Recovery - Tales from the TrenchesAHA Webinar

26jun12:00 pm1:00 pmProtecting Mothers: Key Takeaways From the 2024 Maternal Mortality and Morbidity Prevention ReportAHA Webinar

27jun11:00 am12:00 pmHire Smart: How to Interview, Select, and Onboard the Right PeopleSDAHO Webinar

27jun11:30 am12:30 pmPsychosocial Needs of Cancer Patients from an Ethnically Diverse Underserved CommunityMJHS Hospice and Palliative Care Webinar


By submitting this form, you are consenting to receive marketing emails from: . You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact